Search Within

Isabelle C Riviere

  1. "Jae Park"
  2. "Center for Hematologic Malignancies"
  3. "Claudia Diamonte"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (1)
  3. Research Letter (1)
Groups
  1. Adult Leukemia (17)
  2. Advanced Practice Providers (17)
  3. Center for Hematologic Malignancies (17)
  4. Department of Medicine (17)
  5. GSK Faculty (17)
  6. Hematologic Malignancies Research (17)

More Groups

People
  1. Claudia Diamonte (17)
  2. Jae Park (17)
  3. Renier Brentjens (17)
  4. Elizabeth Halton (16)
  5. Xiuyan Wang (13)
  6. Brigitte Senechal (12)

More People

Years
  1. 2021 (3)
  2. 2020 (2)
  3. 2019 (3)
  4. 2018 (4)
  5. 2017 (5)
Publications
  1. Blood (8)
  2. Journal of Clinical Oncology (5)
  3. Gynecologic Oncology (1)
  4. Hematological Oncology (1)
  5. Leukemia (1)
  6. Neurology (1)
Publishers
  1. American Society of Hematology (8)
  2. American Society of Clinical Oncology (5)
  3. Elsevier Inc. (1)
  4. Lippincott Williams & Wilkins (1)
  5. Nature Publishing Group (1)
  6. Wiley Blackwell (1)

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
    Research Letter

    Perica, K.; Flynn, J.; Curran, K. J.; Rivere, I.; Wang, X.; Senechal, B.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)
    Meeting Abstract

    O'Cearbhaill, R. E.; Park, J. H.; Halton, E. F.; Diamonte, C. R.; Mead, E.; Lakhman, Y.; Kane, P.; Riviere, I. C.; Brentjens, R. J.
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Clinical factors associated with improved survival following allogeneic HSCT after CD19 CAR therapy in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Flynn, J.; Gonen, M.; Bernal, Y.; Diamonte, C.; Halton, E.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R. J.
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL
    Meeting Abstract

    Perica, K.; Flynn, J.; Curran, K. J.; Wang, X.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; Gonen, M.; Riviere, I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save